

FORM NUM: 500.1.03

Academic Personnel Short Profile / Short CV

| University: | University of Nicosia |
|----------------------|-----------------------------|
| Surname: | Siakallis |
| Name: | Georgios |
| Rank/Position: | Clinical Associate |
| Faculty: | Medical School |
| Department: | Basic and Clinical Sciences |
| Scientific Domain: * | Infectious Diseases |

* Field of Specialization

| Academic qualifications (list by highest qualification) | | | | |
|--|------|-----------------------------|--|---|
| Qualification | Year | Awarding Institution | Department | Thesis title (Optional Entry) |
| Infectious Diseases specialty | 2018 | Hellenic Ministry of Health | Attikon University Hospital, Athens, Greece | |
| Internal Medicine specialty | 2015 | Hellenic Ministry of Health | PAGNI, University Hospital of Heraklion, Crete, Greece | |
| MSc in Molecular Basis of Human Diseases | 2009 | University of Crete | Medical School | "Role of TGF-β on HSV-1 progeny viral yield during lytic infection" |
| Medical Diploma | 2006 | University of Crete | Medical school | |

| Employment history in Academic Institutions/Research Centers – List by the three (3) most recent | | | | |
|--|----------------------|--|---|--|
| Period of employ | Period of employment | | Location | Desition |
| From | То | Employer | Eocation | Position |
| 2019 | now | SHSO | Grigorios HIV reference clinic, Larnaca General Hospital | Infectious Diseases consultant |
| 2018 | now | University of Nicosia, Medical School | Nicosia, Cyprus | Clinical Associate for Infectious Diseases and Clinical Microbiology |

| 2015 | 2018 | Attikon, University Hospital, Athens, Greece | Athens, Greece | Infectious Diseases fellow |
|------|------|---|-------------------|-------------------------------|
| 2009 | 2015 | PAGNI, University Hospital, Heraklion, Crete, Greece | Heraklion, Greece | Internal Medicine Resident |

| Key <u>refereed</u> jou | Key <u>refereed</u> journal papers, monographs, books, conference publications etc. List the five (5) more recent and other five (5) selected –(max total 10) | | | | | | |
|-------------------------|--|---|---|--|-----------------|---------------|--|
| Ref. Number | Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages | |
| 1 | 2016 | HIV/AIDS of the Central Nervous System | Tsiodras S. | International Encyclopaedia of Public health | 2 nd edition | | |
| 2 | 2017 | Nebulized antibiotics in mechanically ventilated patients: roadmaps and challenges | Poulakou G. | Expert review of anti- infective therapy | 15 | 211- 229 | |
| 3 | 2017 | Child refugees in Europe and Infectious Diseases: Threat or Threatened | Spernovasilis N. | International Journal of School Health – book chapter | | | |
| 4 | 2017 | Inhaled Antimicrobial for Ventilatorassociated pneumonia: Practical aspects | Poulakou G, Matthaiou DK, Nicolaou DP. | Drugs | 13 | 1399- 1412 | |
| 5 | 2018 | Antimicrobial resistance in intraabdominal infections | Poulakou G. | Abdominal sepsis: a multidisciplinary approach – book chapter | | | |
| 6 | 2018 | ABCs of Sepsis | Thomas K. | Book translation in Greek | | | |
| 7 | 2019 | Intravenous colistin use for infections due to MDR Gram- negative bacilli in critically ill paediatric patients: a | Karageorgos SA et al. | Journal of Antimicrobial Chemotherapy | | | |

| | | systematic review and meta- analysis | | | |
|----|------|--|-----------------------|--|--|
| 8 | 2022 | Gut and airway microbiota and their role in COVID-19 infection and pathogenesis: a scoping review | Liu TFD et al. | Infection | |
| 9 | 2022 | SARS-CoV-2-induced viral sepsis: the role of gut barrier dysfunction | Assimakopoulos et al. | Microorganisms | |
| 10 | 2022 | HIV/AIDS of the Central Nervous System | | International Encyclopaedia of Public Health | |

| | Exhibitions (where applicable). List the five (5) more recent and other five (5) selected. (max total 10) | | | | | |
|-------------|--|-------|-----------------------|-----------|--------------------|--|
| Ref. Number | Date | Торіс | International / Local | Location* | Role in Exhibition | |
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| 5 | | | | | | |
| 6 | | | | | | |
| 7 | | | | | | |
| 8 | | | | | | |
| 9 | | | | | | |
| 10 | | | | | | |

*Specify venue, geographic location etc

| Research Projects. List the five (5) more recent and other five (5) selected (max total 10) | | | | |
|---|------|-------|-----------|---------------|
| Ref. Number | Date | Title | Funded by | Project Role* |

| 1 | 2015-2018 | HIVICUS study (contacted with ESCMID study group for infections in critically ill patients – ESGCIP). Multicentre prospective observational study for HIV positive patients admitted in ICUs. | ESGCIP | Data Manager |
|---|-----------|---|----------|------------------|
| 2 | 2016 | RESCUING study, "A retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria", NCT02641015, year 2016. | Combacte | Sub-investigator |
| 3 | 2015-2016 | CARE study, "A Phase III, multicentre, randomized, open-label study to evaluate the efficacy and safety of Plazomicin compared with Colistin in patients with infection due to CarbapenemResistant Enterobacteriaceae (CRE)". NCT01970371 | Achaogen | Sub-investigator |
| 4 | 2016-2017 | NHS INSIGHT 002 FLU - plus study, an "international observational study to characterize adults with influenza or other targeted respiratory viruses" NCT01056354 | NHS | Sub-investigator |
| 5 | 2016-2017 | NHS INSIGHT 003 FLU-plus study, a prospective "international observational study to characterize adults who are hospitalized with influenza or other targeted respiratory viruses" NCT 01056185 | NHS | Sub-investigator |
| 6 | 2016-2017 | NHS INSIGHT 006 FLU-IVIG study, Phase III clinical trial "Evaluating the safety and efficacy of anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in adults hospitalized with influenza" NCT02287467 | NHS | Sub-investigator |
| 7 | 2017-2018 | Phase III clinical trial "Safety, Tolerability and Efficacy on LDL-C of evolocumab in subjects with HIV and hyperlipidemia/mixed dyslipidemia" NCT02833844 | Amgen | Sub-investigator |

| 8 | 2021-2022 | Holistic assessment of people living with HIV: a cross sectional study | Gilead | Co-ordinator for Cypriot data |
|----|-----------|--|--------|-------------------------------|
| 9 | | | | |
| 10 | | | | |

*Project Role: i.e. Scientific/Project Coordinator, Research Team Member, Researcher, Assistant Researcher, other

| Aca | Academic Consulting Services and/or Participation in Councils / Boards/ Editorial Committees. List the five (5) more recent (Optional Entry) | | | | |
|-------------|---|-----------------------|---|---|--|
| Ref. Number | Period | Organization | Title of Position or Service | Key Activities | |
| 1 | 2020-now | SHSO | Member of SHSO COVID-19 task force | Clinical management of COVID-19 patients | |
| 2 | 2021-now | Ministry of Health | HIV and Sexually Transmitted Infections national focal point | National focal point for HIV infection and STIs (ecdc link) | |
| 3 | | | | | |
| 4 | | | | | |
| 5 | | | | | |

| Award | Awards / International Recognition (where applicable). List the five (5) more recent and other five (5) selected. (max total 10) (Optional Entry) | | | | | |
|----------------|--|---|-------------|--|--|--|
| Ref. Number | Date | Title | Awarded by: | | | |
| 1 | 2016 | EACS (European AIDS Clinical Society) scholarship for participation in the "advanced HIV course and the European clinical research course" | EACS | | | |
| 2 | 2016 | Chosen by Gilead as the Greek representative of the "VOICE 2016". A CPD certified clinical | Gilead | | | |

| | | research training program that aims to develop the HIV research leaders of tomorrow. | |
|----|------|--|------------------------------------|
| 3 | 2016 | Poster entitled "Quantifying fracture risk in clinical practice: treatment for osteoporosis should be considered in approximately 1 out of 4 HIV+ individuals ≥40yrs" was chosen by Gilead as one of the Top 10 amongst thousands at the "HIV Drug Therapy" | Gilead |
| 4 | 2022 | Abstract entitled "Achieving the 95-95-95 HIV cascade of care targets will not be enough to meet the incidence reduction goal among MSM in Cyprus", chosen as one of the best 300 posters | 24th International AIDS conference |
| 5 | | | |
| 6 | | | |
| 7 | | | |
| 8 | | | |
| 9 | | | |
| 10 | | | |

| | Other Achievements. List the five (5) more recent and other five (5) selected. (max total 10) (Optional Entry) | | | | | | | |
|----------------|---|---|-----------------|--|--|--|--|--|
| Ref. Number | Date | Title | Key Activities: | | | | | |
| 1 | 2022 | General Secretary of Cyprus Society of Clinical Microbiology and Infectious Diseases | | | | | | |
| 2 | | | | | | | | |
| 3 | | | | | | | | |
| 4 | | | | | | | | |
| 5 | | | | | | | | |
| 6 | | | | | | | | |
| 7 | | | | | | | | |
| 8 | | | | | | | | |
| 9 | | | | | | | | |

| 10 | | |
|----|--|--|
| | | |